Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
in the muscle in the upper arm instead of the subcutaneous area; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a patient who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix. On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: in the muscle in the upper arm instead of the subcutaneous area). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-FEB-2025 The pharmacist reported that a patient mentioned they got the new Measles, Mumps, and Rubella Vaccine in the muscle in the upper arm instead of the subcutaneous area which led to subcutaneous injection formulation administered by other route. The patient mentioned that vaccine comes in a vial with a syringe, but they were not sure of the brand name and did not provide a lot number. The pharmacist enquired if it was Priorix, the patient said that probably that was the one they got.